Welcome to Vertex Pharmaceuticals.

We believe that, just maybe, we can bring about a profound change in the treatment of serious diseases. This takes cutting-edge science and breakthrough therapies. We’ve built a worldwide community of top researchers and institutions that share our vision for change. With this approach, we think transformative solutions can be achieved even if there is never a “perfect cure.”

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and cystic fibrosis. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Product Pipeline

The Company is leading the development of the HCV protease inhibitor telaprevir (VX-950), which is currently in Phase 3 clinical development. In addition, Vertex is focused on the development of VX-770 and VX-809, two novel drug candidates targeting cystic fibrosis, or CF; VX-500 and VX-813, two second-generation HCV protease inhibitors; and VX-509, a novel Janus kinase 3, or JAK3, inhibitor that targets immune-mediated inflammatory diseases, or IMID.

Vertex has a worldwide collaboration with Merck & Co. for the development of Aurora kinase inhibitors for the treatment of cancer. Vertex is also collaborating with Avalon Pharmaceuticals on the development of AVN-944 (VX-944), an IMPDH inhibitor targeting hematologic cancers.

Worldwide Locations

Cambridge, MA, USA
San Diego, CA, USA
Abingdon, Oxfordshire, UK
Coralville, IA, USA